Brooks Laboratories Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Brooks Laboratories.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth	22.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Brooks Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:BROOKS - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	782	-199	-21	-15	N/A
6/30/2024	817	-175	N/A	N/A	N/A
3/31/2024	795	-196	-101	-97	N/A
12/31/2023	745	-143	N/A	N/A	N/A
9/30/2023	680	-154	-35	-221	N/A
6/30/2023	618	-185	N/A	N/A	N/A
3/31/2023	632	-209	-150	-145	N/A
12/31/2022	790	-202	N/A	N/A	N/A
9/30/2022	827	-218	-837	-528	N/A
6/30/2022	865	-219	N/A	N/A	N/A
3/31/2022	912	-113	-651	-374	N/A
12/31/2021	778	-299	N/A	N/A	N/A
9/30/2021	788	-258	-32	177	N/A
6/30/2021	872	-176	N/A	N/A	N/A
3/31/2021	772	-194	-12	45	N/A
12/31/2020	815	-180	N/A	N/A	N/A
9/30/2020	808	-183	-103	-94	N/A
6/30/2020	653	-235	N/A	N/A	N/A
3/31/2020	697	-244	-120	-94	N/A
12/31/2019	660	-154	N/A	N/A	N/A
9/30/2019	612	-149	N/A	N/A	N/A
6/30/2019	612	-148	N/A	N/A	N/A
3/31/2019	550	-148	-59	-50	N/A
12/31/2018	544	-101	N/A	N/A	N/A
9/30/2018	602	-106	N/A	N/A	N/A
6/30/2018	592	-116	N/A	N/A	N/A
3/31/2018	557	-138	N/A	-62	N/A
12/31/2017	555	-124	N/A	N/A	N/A
9/30/2017	487	-93	N/A	N/A	N/A
6/30/2017	493	-56	N/A	N/A	N/A
3/31/2017	575	17	N/A	96	N/A
12/31/2016	639	75	N/A	N/A	N/A
9/30/2016	707	98	N/A	N/A	N/A
6/30/2016	774	108	N/A	N/A	N/A
3/31/2016	800	106	N/A	81	N/A
12/31/2015	828	84	N/A	N/A	N/A
9/30/2015	856	73	N/A	N/A	N/A
6/30/2015	867	94	N/A	N/A	N/A
3/31/2015	852	95	N/A	21	N/A
12/31/2014	805	91	N/A	N/A	N/A
9/30/2014	760	88	N/A	N/A	N/A
6/30/2014	796	69	N/A	N/A	N/A
3/31/2014	853	72	N/A	107	N/A
12/31/2013	888	49	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BROOKS's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if BROOKS's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if BROOKS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BROOKS's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if BROOKS's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BROOKS's Return on Equity is forecast to be high in 3 years time

Brooks Laboratories Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Insider recently sold ₹66m worth of stock

Second quarter 2025 earnings released: ₹1.51 loss per share (vs ₹0.64 loss in 2Q 2024)

Brooks Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024

Brooks Laboratories Limited Announces Cessation of Sonia Gupta as Independent Director

Brooks Laboratories Limited Announces Board Appointments

New minor risk - Share price stability

High number of new and inexperienced directors

Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024

First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)

Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023)

Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023)

Brooks Laboratories Limited Announces Director Appointments

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

New minor risk - Shareholder dilution

Brooks Laboratories Limited Approves the Appointment of Bhushan Singh Rana as an Additional Director (Executive)

First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023)

Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Brooks Laboratories Limited Appoints Durga Shankar Maity as Additional Director

Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022)

Brooks Laboratories Limited Appoints Kaushalya Singh as a Whole Time Director of the Company

Brooks Laboratories Limited Announces Resignation of Atul Ranchal as Chairman, Effective on November 23, 2022

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Brooks Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022)

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021)

Jyoti Sancheti Resigns as Company Secretary & Compliance Officer of Brooks Laboratories Limited, with Effect from 7 June, 2022

Brooks Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Brooks Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021)

Less than half of directors are independent

Technical Director & Whole Time Director Suresh Garg has left the company

Insufficient new directors

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020)

Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020)

New 90-day low: ₹58.60

Brooks Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

New 90-day high: ₹73.20

New 90-day high: ₹71.75

New 90-day high: ₹68.75

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Brooks Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

First quarter earnings released

New 90-day high: ₹44.65

Brooks Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Full year earnings released - ₹13.84 loss per share

New 90-day high - ₹37.80

Full year earnings released - ₹13.84 loss per share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies